Unclear study priorities
Several possible studies but no clear sequence or decision framework.
INDEPENDENT PRECLINICAL DEVELOPMENT SUPPORT
Preclinical development,
made clearer.
Synprecia helps biotechnology, pharmaceutical and life-science companies design stronger preclinical programs, select the right scientific partners, coordinate outsourced studies and make clearer development decisions.
Independent perspectiveRecommendations shaped by the program.
Scientific structureClear questions and decision criteria.
Coordinated executionAlignment across specialist contributors.
Actionable interpretationEvidence focused on the next decision.
WHAT SYNPRECIA DOES
A connected approach to complex preclinical programs.
Preclinical development often requires multiple disciplines, providers and decisions to move in the same direction.
Synprecia supports companies in defining what needs to be learned, how evidence should be generated, which external partners suit the work and how results should inform the next stage.
Built around your program, not around a fixed laboratory menu.
COMMON DEVELOPMENT CHALLENGES
From fragmented activity to a clearer development path.
Synprecia is designed for situations in which scientific complexity, external dependencies or incomplete information make progress difficult.
Difficult CRO selection
Proposals vary in approach, scope, timing and cost.
Fragmented outsourcing
Several contributors, but no single scientific thread.
Inconclusive results
Ambiguous or unexpected findings need independent interpretation.
Limited internal capacity
Experienced support is needed without immediate permanent expansion.
Program delays
Vendor issues and dependencies put milestones at risk.
CORE SERVICES
Scientific strategy supported by practical execution.
Support for an individual question, a study package or a broader outsourced development program.
Preclinical Development Strategy
Translate program objectives into a structured roadmap with defined evidence needs, priorities, dependencies and decision points.
Study Design and Protocol Review
Develop or independently review study concepts, models, endpoints, controls, dose rationale and acceptance criteria.
CRO and Vendor Selection
Identify suitable providers, structure requests for proposal and compare scientific fit, readiness, timing and cost.
Study Oversight and Project Management
Maintain scientific and operational alignment from kickoff through data delivery, issue management and milestone review.
Data Review and Scientific Interpretation
Assess data quality, integrate findings across workstreams and clarify implications for further development.
Scientific Due Diligence
Provide an independent assessment of scientific rationale, evidence quality, development assumptions, risks and remaining gaps.
Troubleshooting and Program Rescue
Investigate underperforming studies, identify probable causes and define a proportionate recovery plan.
Fractional Preclinical Leadership
Add flexible senior-level scientific coordination for a defined period or development objective.
SCIENTIFIC CAPABILITIES
The right expertise for each development question.
Synprecia helps define the required combination of models, technologies and specialist knowledge.
Specific activities are assessed program by program and may be delivered by Synprecia specialists or coordinated through selected CROs, laboratories and subject-matter experts.
HOW WE WORK
A five-stage path from uncertainty to decision.
Understand
Clarify the asset, scientific rationale, development context, available evidence and immediate business objectives.
Assess
Review existing data, assumptions, dependencies, scientific gaps and material risks.
Plan
Define the questions, studies, sequence of work and decision criteria.
Coordinate
Align selected providers, protocols, timelines, responsibilities and communication.
Decide
Integrate results, assess confidence and determine the most appropriate next step.
WHO WE SUPPORT
Designed for innovative teams at critical decision points.
Emerging biotechnology companies
Build a robust approach without creating every capability internally.
Pharmaceutical teams
Add independent review or flexible capacity around a defined program.
University spin-offs
Convert promising academic evidence into a structured development plan.
Investors and venture builders
Evaluate evidence strength, assumptions, risks and capital needs.
International companies
Coordinate specialist support through one scientific interface.
CROs and laboratories
Collaborate where complementary expertise or coordination is required.
CONFIDENTIALITY
Scientific discussions require discretion.
Synprecia treats early conversations with care. An appropriate confidentiality agreement can be established before sensitive materials are exchanged.
Please do not include confidential study data, unpublished intellectual property or patient information in the public contact form.
Start a Confidential ConversationINSIGHTS
Practical perspectives on preclinical decision-making.
What Makes a Preclinical Plan Decision-Ready?
A useful plan connects each activity to a specific uncertainty, decision and development consequence.
Read article →Selecting the Right CRO: Scientific Fit Before Price
The lowest quotation is not always the lowest-risk choice. Technical fit, communication and data usability matter.
Read article →When a Study Underperforms: A Structured Rescue Approach
Unexpected data should trigger disciplined diagnosis rather than immediate repetition of the same design.
Read article →START A CONVERSATION
Let’s clarify the next step in your preclinical program.
Tell us where the program stands, what you need to learn and which challenges are slowing progress.